Study of pirtobrutinib for B-cell lymphoma after other treatments fail
Treatments studied
Part of Cancer clinical trials.
This study tests a new drug, pirtobrutinib, for people with certain types of B-cell lymphoma who have already tried a similar drug (called a BTK inhibitor) and it stopped working or caused side effects. The goal is to see how well it works in real life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of B-cell lymphoma, such as CLL/SLL, MCL, FL, MZL, or WM/LPL.
- You have already been treated with a BTK inhibitor (like ibrutinib or zanubrutinib) and your cancer grew or you couldn't tolerate it.
- You are generally able to care for yourself (ECOG score 0-2).
- Your liver and kidney function are within acceptable limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It is for those whose cancer has come back or not responded to treatment, including a prior BTK inhibitor, and also for those who have never been treated but have a specific genetic change (17p deletion).
This study tests a new oral medication called pirtobrutinib in people with previously untreated CLL or SLL. Researchers will collect blood and lymph node samples to understand how the immune system responds to the drug.
This trial tests a new drug, pirtobrutinib, for people with chronic lymphocytic leukemia (CLL) who have already been treated with zanubrutinib (a similar BTK inhibitor). The goal is to see if switching to pirtobrutinib can help control the disease.
This trial tests a new pill, pirtobrutinib, for people 75 or older with chronic lymphocytic leukemia (CLL) who have never had treatment before. The goal is to see if it helps control the disease with manageable side effects.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
Hear when a new Mature B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.